We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Synaffix

News List

Synaffix, MacroGenics Ink Deal to Enable Next-Gen ADCs contractpharma
February 04, 2022
Synaffix to provide access to antibody-drug conjugate (ADC) technologies in deal valued at up to $586 million.
Genmab Gains Broad Access to Synaffix's ADC Technologies contractpharma
January 04, 2022
Secures rights for conducting research on ADCs against multiple drug targets under new licensing agreement.
Innovent Biologics Signs License Agreement with Synaffix contractpharma
July 02, 2021
Synaffix will provide proprietary ADC technologies to enable Innovent to rapidly progress one of its antibodies as a best-in-class ADC candidate.
Innovent Announces License Agreement with Synaffix in an ADC Technology Deal prnasia
June 29, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced the signing of ...
Abzena Completes ADC Tech Transfer contractpharma
July 24, 2019
Successful technical transfer of Synaffix GlycoConnect ADC Technology to enable use in client projects.
Synaffix announces license agreement with Miracogen worth $125M biospectrumasia
April 14, 2019
Miracogen will be responsible for the research, development, manufacturing and commercialization of the ADC product